SPONSORS

The scientific committee would like to thank the support of our sponsors for the 2019 AUS MRinRT Meeting.

GOLD SPONSORS



SILVER SPONSORS



BRONZE SPONSORS



TUESDAY

12:30		Lunch	40
13:10		Collaborators Meeting	90
14:40		Afternoon Tea	20
	MRI Biomarkers 1		
15:00	Uulke van der Heide	The promise and challenges of in-room functional imaging for MRI-Linac radiotherapy	40
	Shivani Kumar	Radiation induced lung injury comparison between MRI and CT during and post treatment	12
	Lois Holloway	Multiparametric serial magnetic resonance imaging assessment of gross tumour volume and hippocampal changes over the course of adjuvant brain cancer radiotherapy	12
	Trang Pham	MRI tumour heterogeneity analysis for prediction of chemoradiotherapy response and disease free survival in rectal cancer	12
	Hilary Byrne	MRI-Linac radio-enhancement with theranostic gadolinium-based nanoparticles: pre-clinical evaluation in the Australian MRI-Linac	12
	James Korte	Auto-contouring head and neck cancer patient organs at risk on T2 weighted magnetic resonance imaging	12
	Urszula Jelen	Dosimetry for the first live irradiation on the Australian MRI-Linac	12
17:00		Finish	
	Dinner	Self-directed, Hastings Street	

WEDNESDAY

	Novel Treatment Techniques		
8:30	Simon Puttick	Developing peptide receptor radionuclide therapies for personalised cancer therapy	40
	Alexandra Berlangieri	A scoping review of MRI guided breast radiotherapy	12
	Laura O'Connor	MARVEL: MRI only planning for anal canal, rectum, cervix and endometrium, radiation therapy treatments	12
	Peter Greer	A multi-centre prospective study for implementation of an MRI-only prostate treatment planning workflow	12
	Matt Richardson	Visualising the urethra for prostate radiotherapy	12
	Laura O'Connor	A preliminary evaluation of a commercially available synthetic CT generation method for prostate cancer	12
	Suzanne Lydiard	MR-Guided stereotactic arrhythmic radioblation (STAR) for atrial fibrillation: Preliminary imaging finding in AF patients	12
10:30		Morning Tea	20
	Engineering 1		
10:50	Uulke van der	The clinical implementation of MRI-Linac	
	Heide	radiotherapy: the Netherlands Cancer	40
			40
	Heide	radiotherapy: the Netherlands Cancer Institute Experience	
	Heide Brad Oborn	radiotherapy: the Netherlands Cancer Institute Experience MRI guided protons Development of an MRI distortion	20
	Heide Brad Oborn Amy Walker	radiotherapy: the Netherlands Cancer Institute Experience MRI guided protons Development of an MRI distortion assessment tool (MR-DAT) Pelvic organ motion under horizontal rotation – towards gantry free therapy: Initial	20 12
	Heide Brad Oborn Amy Walker Jarryd Buckley	radiotherapy: the Netherlands Cancer Institute Experience MRI guided protons Development of an MRI distortion assessment tool (MR-DAT) Pelvic organ motion under horizontal rotation – towards gantry free therapy: Initial results Real-time target tracking for the Australian	20 12 12
	Heide Brad Oborn Amy Walker Jarryd Buckley Paul Liu	radiotherapy: the Netherlands Cancer Institute Experience MRI guided protons Development of an MRI distortion assessment tool (MR-DAT) Pelvic organ motion under horizontal rotation – towards gantry free therapy: Initial results Real-time target tracking for the Australian MRI-Linac Comparison of 4D-CT and 4D-MRI for tumour motion measurement: A phantom	20 12 12 12
12:50	Heide Brad Oborn Amy Walker Jarryd Buckley Paul Liu Terry Perkins	radiotherapy: the Netherlands Cancer Institute Experience MRI guided protons Development of an MRI distortion assessment tool (MR-DAT) Pelvic organ motion under horizontal rotation – towards gantry free therapy: Initial results Real-time target tracking for the Australian MRI-Linac Comparison of 4D-CT and 4D-MRI for tumour motion measurement: A phantom study 4D Radiation Dosimetry with MRI Polymer	20 12 12 12 12

	Clinical Implementation in Australia		
13:30	Olga Green	The clinical implementation of MRI-Linac Radiotherapy: The Washington University Experience	40
	Kristie Harrison	Update on Genesis Care MRL	12
	Farshad Foroudi	TROG MRI in RT Interest Group	12
	Trang Pham	MANTRA and Liver	12
	Kate Skehan/ Robba Rai	Consensus on Training and Safety for Radiation Oncology staff	40
15:30		Afternoon Tea	
	MRI Biomarkers 2		
15:45	Robba Rai	Multicentre evaluation of radiomic features in MRI	12
	Nathan Hearn	Feasibility of integrating routine diagnostic functional magnetic resonance imaging for novel applications in head and neck radiation therapy	12
	Monchai Phonlakrai	Quantification of liver function using MRI- based functional parameters for radiation- associated injury following radiotherapy: a feasibility study	12
	Neda Gholizadeh	Evaluation of glucose chemical exchange saturation transfer (gluco-CEST) imaging at 3T	12
	Kate Skehan	PET/CT vs DWI MRI for Oesophageal GTV Delineation – A Pilot comparative study	12
	Neda Gholizadeh	Localisation of central gland prostate cancer using multiparametric magnetic resonance imaging (mp-MRI)	12
	Hongfu Sun	Differentiation hemorrhage, calcification and edema of glioblastoma using quantitative susceptibility mapping (QSM)	12
	Trang Pham	Ultra-high field MRI aided biomarker discovery in rectal cancer	12
17:30		Finish	
19:00		Group Conference Dinner – Hawaiian Themed	

THURSDAY

	Engineering 2		
9:00	John Baines	The elekta unity MR-Linac install at Townsville hospital	12
	Amy Walker	Dosimetric impact of setup and geometric distortion on MRI-based planning for Lung Cancer Radiotherapy	12
	ShanShan Shan	Efficiency improvement for gradient nonlinearity (GNL) correction with non-uniform faster fourier transform (NUFFT)	12
	Mingyan Li	The design of a universal toros radiofrequency (RF) coil array for the Australian MRI-Linac System	12
	Xinwen Liu	Accelerating region-of-interest image reconstruction via deep learning for MR Guided Radiotherapy	12
	Elizabeth Patterson	Off axis surface dosimetry on the Australian MRI-Linac	12
	Adam McNeilly	Investigations of an Epid based 3D dose reconstruction method for applications in MR-Linac radiotherapy	12
10:30		Morning Tea	20
	Quality Assurance		
10:50	Olga Green	The MRI-Linac adaptive radiotherapy process: lessons learned and clinical implications	40
	Urszula Jelen	Dosimetric commissioning of the Australian MRI-Linac status update	12
	Rhonda Brown	Audit development for MRI-Linacs	12
	Jae Choi	Patient specific quality assurance of synthetic CT using bulk density method in MRI-only workflow for prostate radiation therapy	12
	Georgia Barjaktarovic	The Townsville cancer centre's preparation and implementation of the Elekta Unity MRI-Linac	12
	Jarrad Begg	Direct measurement of the magnetic field correlation factor, Kb, for a Roos Chamber on an inline MRI-Linac	12
	Yu Feng Wang	Quality assurance of multiparametric	

12:50		Lunch	40
13:30	TROG MRI Group	Optional Attendance	60
14:30		Finish	

GUEST SPEAKERS



Olga Green, PhD is an assistant professor of radiation oncology and Associate Director of the Medical Physics Residency Program. Professor Green joined the faculty in 2011. She earned a PhD in Experimental Nuclear Physics in 2008 from Washington University in St. Louis and completed her residency in medical physics, CAMPEP accredited, at Washington University School of Medicine in 2011. She is certified in Therapeutic Radiological Physics by the American Board of Radiology. Dr. Green's clinical work and research focuses on magnetic resonance image-guided radiation therapy. She is the lead authorized medical physicist for the first-in-the world MR-IGRT system.

Olga's visit and attendance at our meeting is sponsored by Elekta.



Dr Simon Puttick's research is centered around the development of advanced therapies for brain cancers guided by medical imaging technologies. His projects include the development of theranostics based on engineered antibodies, the development of MRI and PET imaging acquisition schemes that highlight physiological heterogeneity in brain tumours to predict treatment efficacy, the development of actively triggered drug releasing implants for brain cancers and the development of comparative neuro-oncology trials for more effective translation of promising therapies to the clinic.

Dr Simon Puttick completed his PhD under the supervision of Professor Peter Licence at the University of Nottingham in July 2012. Following his PhD he moved to the Wolfson Brain Imaging Centre at the University of Cambridge as a Research Fellow under the supervision of Professor A. Jennifer Morton where his research was focussed on the development of MRI biomarkers of neural degeneration in Huntingtons disease. He moved to the AIBN in January 2013 as a Research Fellow in Professor Andrew Whittakers group focussed on the development of theranostics for brain cancers. Dr Puttick is currently employed as an AIBN-CSIRO Research Fellow working within Professor Whittakers group and the CSIRO Probing Biosystems Future Science Platform where he leads a program of research focussed on the development of advanced therapies for brain cancers.



Uulke van der Heide received his PhD degree (cum laude) in the field of molecular biophysics from the Utrecht University in 1993. He subsequently worked as a post-doc at the physiology departments of the University Medical Center in Utrecht and at the University of Pennsylvania in Philadelphia, US, on the molecular mechanism of motor proteins

In 1999 he moved to the field of radiation oncology, as a resident medical physicist at the University Medical Center in Utrecht. He got his license in 2003. Between 2003 and 2011 he worked as a medical physicist and researcher in the same department, working on MRI-guided radiotherapy, focusing on prostate cancer. Together with Marco van Vulpen he initiated the phase III FLAME trial for focal boosting of prostate cancer.

In 2011 he moved to the Netherlands Cancer Institute as a medical physicist and group leader, working on MRI-guided radiotherapy. In this capacity he is project leader of the MR-Linac project. His research focusses on quantitative MRI techniques for tumor characterization and response monitoring of radiotherapy. In August 2015 he was appointed professor of imaging technology in radiation oncology at the Leiden University Medical Center.

Uulke's visit and attendance at our meeting is sponsored by Device Technologies.

NOTES